Free Trial

ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals logo
$10.11 -0.86 (-7.84%)
Closing price 04:00 PM Eastern
Extended Trading
$10.50 +0.39 (+3.86%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRY vs. AKRO, KYMR, MENS, CRNX, NAMS, VKTX, LNTH, MIRM, ZLAB, and ADMA

Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Akero Therapeutics (AKRO), Kymera Therapeutics (KYMR), Jyong Biotech (MENS), Crinetics Pharmaceuticals (CRNX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), Zai Lab (ZLAB), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

ARS Pharmaceuticals vs. Its Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

ARS Pharmaceuticals has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARS Pharmaceuticals$89.15M11.21$8M-$0.49-20.63
Akero TherapeuticsN/AN/A-$252.06M-$2.00-26.83

In the previous week, Akero Therapeutics had 25 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 28 mentions for Akero Therapeutics and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.98 beat Akero Therapeutics' score of 0.22 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ARS Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Akero Therapeutics
8 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

ARS Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.

ARS Pharmaceuticals presently has a consensus price target of $33.80, indicating a potential upside of 234.32%. Akero Therapeutics has a consensus price target of $73.38, indicating a potential upside of 36.74%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Akero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ARS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Akero Therapeutics
1 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.31

Akero Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. Akero Therapeutics' return on equity of -15.84% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ARS Pharmaceuticals-42.74% -21.85% -15.88%
Akero Therapeutics N/A -15.84%-14.59%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ARS Pharmaceuticals beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRY vs. The Competition

MetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$999.17M$3.02B$6.13B$10.46B
Dividend YieldN/A57.77%5.73%4.78%
P/E Ratio-20.6322.9485.0627.23
Price / Sales11.21612.73573.27177.38
Price / Cash1,258.81172.6337.3961.86
Price / Book3.835.4112.386.64
Net Income$8M$33.06M$3.32B$276.79M
7 Day Performance-12.69%-2.18%-0.27%-1.54%
1 Month Performance7.44%11.60%9.52%5.44%
1 Year Performance-38.80%-3.20%71.62%36.30%

ARS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRY
ARS Pharmaceuticals
2.9784 of 5 stars
$10.11
-7.8%
$33.80
+234.3%
-28.0%$999.17M$89.15M-20.6390
AKRO
Akero Therapeutics
3.6473 of 5 stars
$53.66
-0.4%
$73.38
+36.7%
+79.1%$4.29BN/A-26.8330Insider Trade
High Trading Volume
KYMR
Kymera Therapeutics
0.801 of 5 stars
$59.89
+4.7%
$61.26
+2.3%
+40.4%$4.28B$44.71M-17.26170Insider Trade
MENS
Jyong Biotech
N/A$55.70
+0.8%
N/AN/A$4.23BN/A0.0031
CRNX
Crinetics Pharmaceuticals
4.1841 of 5 stars
$44.43
-1.1%
$74.45
+67.6%
-23.4%$4.18B$1.39M-10.81210
NAMS
NewAmsterdam Pharma
1.782 of 5 stars
$37.15
+0.3%
$42.00
+13.1%
+112.9%$4.18B$45.56M-22.934News Coverage
High Trading Volume
VKTX
Viking Therapeutics
3.9443 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-46.3%$3.81BN/A-22.1620Upcoming Earnings
LNTH
Lantheus
4.5458 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-49.5%$3.71B$1.53B14.52700Trending News
Analyst Revision
MIRM
Mirum Pharmaceuticals
3.2175 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+91.9%$3.63B$429.16M-59.64140Positive News
Analyst Forecast
Analyst Revision
ZLAB
Zai Lab
2.7445 of 5 stars
$31.23
+3.3%
$56.35
+80.4%
+18.6%$3.49B$398.99M-15.311,869News Coverage
Positive News
ADMA
ADMA Biologics
3.5878 of 5 stars
$14.55
+0.1%
$27.67
+90.1%
-9.0%$3.47B$426.45M16.92530News Coverage

Related Companies and Tools


This page (NASDAQ:SPRY) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners